Jonathan Block
Managing Editor, Sectors at Seeking Alpha
Managing Editor, Sectors and Senior Health Care News Editor at Seeking Alpha. MPH from CUNY Graduate School of Public Health. All opinions are mine.
Articles
-
19 hours ago |
seekingalpha.com | Jonathan Block
hapabapa The U.S. FDA on Wednesday granted accelerated approval to AbbVie's (NYSE:ABBV) Emrelis (telisotuzumab vedotin), an antibody-drug conjugate that is a second-line therapy for non-squamous non-small cell lung cancer with high c-Met protein overexpression. Approval was based on results from a
-
20 hours ago |
seekingalpha.com | Jonathan Block
May 14, 2025 2:08 PM ET, , , , , , , , , , By: , SA News Editormirza kadicTerrance Cole, President Trump's nominee for DEA Administrator, largely sidestepped questions from two Democratic senators regarding marijuana reforms. Sens. Cory Booker (N.J.) and Alex Padilla (Calif.) asked Cole his position on whether he agrees with a proposal to move cannabis from Schedule I to ScheduleSymbolLast Price% Chg--Green Thumb Industries Inc. --Curaleaf Hldgs Inc. --Trulieve Cannabis Corp.
-
21 hours ago |
seekingalpha.com | Jonathan Block
May 14, 2025 12:58 PM ET, , , , , , , , , , By: , SA News EditorSamuel Corum/Getty Images NewsHHS Secretary Robert F. Kennedy Jr. was barraged with questions from lawmakers at a House committee hearing dealing with proposed cuts to health agencies, vaccines, and the measles outbreak. The secretary was appearing before the House Appropriations Committee to discussSymbolLast Price% Chg--Merck & Co., Inc. --Pfizer Inc. --Johnson & Johnson--Bristol-Myers Squibb Company--GSK plc
-
1 day ago |
seekingalpha.com | Jonathan Block
filo GRAIL (NASDAQ:GRAL) is down ~16% in after-hours trading Tuesday after reporting Q1 financial results that missed on the top line. It beat on the bottom line. Q1 revenue of $31.8M was a 19% increase compared to the prior-year period. GAAP
-
2 days ago |
seekingalpha.com | Jonathan Block
GSK (NYSE:GSK) and iTeos Therapeutics (NASDAQ:ITOS) have agreed to discontinue development of a combination of the former's Jemperli (dostarlimab) combined with the experimental candidate belrestotug for PD-L1 high non-small cell lung cancer (NSCLC) after the asset failed to show clinically meaningful
Try JournoFinder For Free
Search and contact over 1M+ journalist profiles, browse 100M+ articles, and unlock powerful PR tools.
Start Your 7-Day Free Trial →X (formerly Twitter)
- Followers
- 449
- Tweets
- 872
- DMs Open
- No
Yet another interesting development involving @CassavaSciences #Alzheimers #CUNY Interesting that $SAVA shares up 12% in Tuesday afternoon trading. https://t.co/cHMREionxh
Exciting news for @GEHealthCare and @VUMCDiscoveries, and promising for using #ai to improve health outcomes for #cancer patients. https://t.co/3necZyZqtn
Antibody-drug conjugates, a relatively new type of cancer treatment, are poised to boost the bottom lines on several pharma and biotech companies. https://t.co/BQPaw7U4Ny